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Total RNA extraction and reversed transcription to cDNA from 3 µg RNA was performed as described (24). The following primer sequences were used: rat/mouse/human GPR103, Fwd: for 30 sec annealing; 72°C for 60 sec, 72°C for 7 min. The final PCR products (318 bp for GPR103, 196 bp for human QRFP, 300 bp for rat QRFP, 199 bp for 18s rRNA) were separated by 1.5%
agarose gel electrophoresis and visualized by ethidium bromide staining.
GPR103 immunofluorescence
INS-1E β-cells and human pancreatic islets were seeded on glass coverslips in complete medium for 2 days, then washed twice with PBS. INS-1E cells were allowed to grow up to 50-60% confluence. The cells were then fixed with 4% paraformaldehyde and incubated with goat anti-GPR103 antibody overnight at 4°C. After washing three times with PBS, cells were incubated with anti-goat secondary TRITC-conjugated antibody (Life Technologies, Milan, Italy) for 1 h at room temperature. Nuclei were stained with 4'-6-diamidino-2-phenylindole (DAPI). Red and blue channels were assigned to GPR103 and nuclei, respectively. Images were taken using a Leica DM200 fluorescent microscope and a Leica DFC340 FX camera. Adult rat hippocampal (AHP) cells were used as positive control.
Results

GPR103 and QRFP are expressed in INS1-E β-cells and human pancreatic islets
RT-PCR analysis showed mRNA expression of both GPR103 and QRFP, the precursor of RF43a and 26RFa, in pancreatic INS1-E β-cells and human pancreatic islets ( Figure 1A and B). At the protein level, Western blot analysis showed presence of both GPR103 and QRFP, the precursor peptide of RF43a and 26RFa, in INS-1E β-cells and human pancreatic islets ( Figure 1 C and D) .
Furthermore, immunofluorescence analysis revealed GPR103 protein expression in both β-cells ( Figure 1E ) and human islets, where GPR103 showed partial colocalization with insulin in β-cells ( Figure 1F ). Immunohistochemical studies also confirmed expression of both GPR103 and QRFP, in INS1-E β-cells and human pancreatic islets ( Figure 1G and H). In human pancreas, GPR103
positivity was found in endocrine pancreatic cells, being negative in acinar cells. Similarly, QRFP was positive in pancreatic islets and negative in acinar cells ( Figure 1H ). Pituitary was used as positive control, showing strong staining for GPR103 in the posterior lobe (neurohypophysis) but almost negative staining in the anterior lobe (adenohypophysis) ( Figure 1H ). QRFP was negative in the neurohypophysis and weakly positive in isolated cell clusters of the adenohypophysis (corresponding to acydophilic cells) ( Figure 1H ).
43RFa and 26RFa both promote survival and proliferation and inhibit apoptosis in INS1-E β-cells
One of the major pathological conditions, responsible for the progression of diabetes, is β-cell loss by apoptosis and decreased β-cell mass. Therefore, we tested the hypothesis as to whether 43RFa and 26RFa may protect β-cells and human pancreatic islets from the harmful effects of stimuli classically involved in diabetes, such as cytokines or glucolipotoxicity.
43RFa and 26RFa effects on survival and proliferation were assessed in INS1-E β-cells cultured in serum-free medium, in either absence or presence of the inflammatory cytokines interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). Serum starvation per cell survival under serum starvation from 10 to 100 nmol/L, as assessed by MTT assay (Figure 2A ).
In cytokine-treated cells, they both promoted survival at all the concentrations tested, showing the greatest effect at 100 nmol/L ( Figure 2B ). Similar results were obtained by performing the Trypan blue assay (data not shown). 43RFa and 26RFa also increased cell proliferation under serum starvation at all the concentrations tested ( Figure 2C ), whereas with cytokines, they were effective from 25 to 100 nmol/L ( Figure 2D ). As for cell survival, the best proliferative effect was observed at 100 nmol/L, for both peptides, with a slight dose-response under cytokine treatment. Notably, under either serum starvation or cytokines, at 100 nmol/L the peptides increased survival and proliferation up to levels comparable to those of serum and serum-free medium, respectively.
The glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 (Ex-4), which exerts antiapoptotic, survival and proliferative effects in β-cells (27), was used as control peptide. The survival and proliferative effects of Ex-4 were comparable to those of 43RFa and 26RFa, particularly at 100 nmol/L (Figure 2A-D) .
Glucolipotoxicity, caused by excessive glucose and/or lipids, is a consequence of type 2 diabetes and a major cause of β-cell dysfunction and death (3) . Based on the results obtained in cytokinetreated cells, 43RFa and 26RFa, were tested at 100 nmol/L, the concentration that was chosen for the following experiments. The peptides equally increased INS-1E β-cell survival and proliferation, that were both reduced in cells incubated with high glucose (30 mM) and palmitate (0.4 mmol/L), compared to serum-free medium alone ( Figure 2E and F). These effects were similar to those of Ex-
4.
As assessed by Hoechst staining of apoptotic nuclei ( Figure 2G ) and caspase 3 activation ( Figure   2H ), apoptosis was increased in cells cultured in serum free medium, compared to those in serum, and even more with cytokines or high glucose/palmitate. Both 43RFa and 26RFa, at 100 nmol/L Under serum starvation, 43RFa and 26RFa increased survival at 100 nmol/L, having no significant effect at lower concentrations ( Figure 3A ). In the presence of cytokines, they both increased cell survival from 25 to 100 nmol/L, which was the best concentration tested ( Figure 3B ). Conversely, Ex-4 was effective at all concentrations in both experimental conditions and in a dose-dependent manner ( Figure 3A and B). At 100 nmol/L, 43RFa-and 26RFa-induced survival was similar to that of Ex-4 and a dose-response was observed under cytokine treatment ( Figure 3B ). 100 nmol/L was also used in islets cultured in high glucose/palmitate, where the peptides equally increased islet cell survival ( Figure 3C ). Apoptosis, assessed by Hoechst staining and caspase-3 activity was inhibited by both 43RFa and 26RFa, in all experimental settings and similarly to Ex-4 ( Figure 3D and E).
These results indicate that, as for β-cells, in human islets 43RFa and 26RFa exert protective effects against different detrimental diabetogenic stimuli. We next investigated the signaling pathways involved in the survival effects of the peptides, and specifically, PI3K/Akt and ERK1/2, whose activation plays a key role in β-cell growth and survival (28-30).
In INS-1E cells, 43RFa increased the phosphorylation of both Akt (at 15 min) and ERK1/2 (5 to 30 min, compared to basal time point) ( Figure 4A and B). 26RFa displayed no effect on Akt, at any time point ( Figure 4C ), whereas it promoted ERK1/2 increase, from 5 to 60 min compared to basal ( Figure 4D ). Similar effects were observed in human pancreatic islets, where 43RFa induced Akt and ERK1/2 phosphorylation (both at 5 to 30 min) ( Figure 4G and H), whereas 26RFa promoted ERK1/2 (5 and 15 min) ( Figure 4J ), but not Akt activation ( Figure 4I ). Accordingly, in both INS-1E
and human islets cultured in serum-free medium ( Figure 4E and K) or in the presence of cytokines ( Figure 4F and L), preincubation with the inhibitors for either Akt (wortmannin) or ERK1/2 (PD98059) blocked the survival action of 43RFa, whereas that of 26RF was reduced only by PD98059 and not by wortmannin. These results suggest that both PI3K/Akt and ERK1/2 are involved in the survival effects of 43RFa, whereas for 26RFa, only ERK1/2 is engaged.
43RFa promotes glucose-stimulated insulin secretion and potentiates Ex-4 insulinotropic action in β-cells and human islets, whereas 26RFa inhibits insulin release and reduces Ex-4 effects
We next sought to determine 43RFa and 26RFa effects on glucose-stimulated insulin secretion (GSIS) in both INS-1E and human pancreatic islets. The peptides were tested at different glucose concentrations, either alone or in combination with Ex-4, that was used as positive control. As expected, Ex-4 increased GSIS at all glucose concentrations, in both β-cells and islets. Similarly, 43RFa increased insulin release at all glucose concentrations in β-cells and islets, to an extent comparable to that of Ex-4. 43RFa even increased basal insulin levels, without glucose stimulation.
Moreover, Ex-4-and 43RFa-induced insulin secretion was further potentiated when Ex-4 and 43RFa were given together, at 15 and 25 mmol/L glucose in INS-1E cells, and at 7.5, 15 and 25
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For Peer Review Only Diabetes mmol/L glucose in human islets ( Figure 5A and B). On the other hand, 26RFa strongly inhibited both basal and GSIS, and dramatically reduced Ex-4 insulinotropic effects at all glucose concentrations, in either INS-1E β-cells or human islets ( Figure 5A and B).
To investigate the signaling pathways involved in the insulinotropic and insulinostatic effects of 43RFa and 26RFa, respectively, INS-1E β-cells and human islet cells were preincubated with either pertussis toxin (PTX), an inhibitor of Gα i/o coupled receptor (31), or with NF449, a selective Gα s protein-coupled receptor antagonist (32) . 43RFa-induced increase of insulin secretion was unaffected by pretreatment with PTX, whereas it was blocked by NF449, in both β-cells and islets.
Conversely, PTX restored up to control levels GSIS, that was inhibited by 26RFa, whereas NF499 had no effect on the insulinostatic action of the peptide ( Figure 5C -F). These results suggest that the opposite effects of 43RFa and 26RFa on insulin secretion involve signaling through Gα s and Gα i/o , respectively. Furthermore, the role of GPR103 in 43RFa and 26RFa effects on GSIS was determined by transfecting INS-1E β-cells with small interfering RNA (siRNA) targeted to GPR103. As assessed by RT-PCR, at 24 after transfection GPR103 mRNA expression was strongly reduced by siGPR103, compared with scrambled (control) siRNA ( Figure 5G ). The insulinotropic effect of 43RFa, assessed at both 0 and 7.5 mmol/L glucose, was completely blocked in siGPR103 cells, as compared to siControl, whereas 26RFa-induced inhibition of GSIS was unchanged in siGPR103 transfected cells ( Figure 5H ). These findings suggest that 43RFa promotes insulin secretion through binding to GPR103, whereas 26RFa inhibits insulin release likely through a different receptor.
43RFa, but not 26RFa, promotes cAMP increase and glucose uptake in β-cells and human pancreatic islets
cAMP elevation is linked to increased insulin secretion in pancreatic β-cells and protection from apoptosis (33, 34) . Therefore, we investigated the effects of 43RFa and 26RFa on cAMP levels in both INS-1E β-cells and human pancreatic islets. In INS-1E β-cells, 43RFa elevated intracellular Glucose uptake by pancreatic β-cells, through the glucose transporter GLUT2 and glucokinase activity, is essential for the normal insulin secretory response to hyperglycemia (35, 36) . To further ascertain the stimulatory and inhibitory roles of 43RFa and 26RFa, respectively, on GSIS, glucose uptake was determined in INS-1E β-cells and human pancreatic islets. In INS-1E β-cells, at 10 min incubation 43RFa increased glucose 2-[ 3 H]-deoxyglucose uptake at 10 nmol/L and showed a remarkable effect at 100 nmol/L, similarly to Ex-4 and to the cAMP analog 8-Br-cAMP. At 5 min, 43RFa had no effect at 10 nmol/L, but stimulated glucose uptake at 100 nmol/L. Conversely, 26RFa had no effect, at any concentration and incubation time tested ( Figure 6E ). Similarly, in human pancreatic islets, that were tested for 10 min with 100 nmol/L of each peptide, 43RFa, but not 26RFa, increased 2-deoxyglucose uptake ( Figure 6F ).
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Discussion
The present study shows that the RFamide peptides 43RFa and 26RFa both display survival and antiapoptotic effects in pancreatic β-cells and human pancreatic islets. Furthermore, 43RFa stimulated, whereas 26RFa inhibited the insulin response to glucose and Ex-4, in both β-cells and human pancreatic islets. These effects involved activation of distinct G proteins and different regulation of cAMP levels and glucose uptake.
In mammals, the mRNAs encoding for the 43RFa and 26RFa precursor (QRFP) and for its receptor GPR103, are mainly expressed in the brain, particularly in the hypothalamus, and in different peripheral organs (6, 9) . QRFP mRNA has been found expressed in mouse and rat pancreas, but not in human pancreas (37) . GPR103 was reported to be absent in human pancreas and expressed at very low level in mouse pancreas (6, 7, 37) . Here we show QRFP and GPR103 expression in both rat INS-1E β-cells and human pancreatic islets, either at mRNA or protein level. Interestingly, in human islets, GPR103 protein co-localized with insulin, suggesting direct interaction of 43RFa and 26RFa with their receptor in β-cells. Furthermore, QRFP expression in β-cells and human islets may suggest autocrine/paracrine effects of the peptides. Accordingly, 26RFa autocrine/paracrine effects have been recently proposed in prostate cancer cells, where the peptide induced cell migration and neuroendocrine differentiation, and in macrophages and adipocytes, where both 43RFa and 26RFa promoted adipogenesis (10, 11, 22) . Future studies will help elucidate whether autocrine/paracrine mechanisms may also occur in pancreatic islets.
We firstly report here the survival and antiapoptotic effects of 43RFa and 26RFa. Pancreatic β-cells and human pancreatic islets were chosen as in vitro models because, besides the survival actions,
we were interested in the metabolic effects of these peptides. Indeed, a role in adipogenesis, lipid metabolism and inflammation, as well as an association between GPR103 and QRFP expression and obesity, have been recently described (10, 11 differently regulated these signaling pathways. In fact, whereas 43RFa increased the phosphorylation of both PI3K/Akt and ERK1/2, 26RFa increased ERK1/2, but not PI3K/Akt.
Accordingly, inhibition of PI3K and ERK1/2 phosphorylation with wortmannin and PD98059, respectively, blocked 43RFa-induced survival, whereas only ERK1/2 inhibitor decreased 26RFa-induced survival. These results indicate that ERK1/2, and not PI3K/Akt, is required for 26RFa survival effect, whereas 43RFa uses both pathways. Notably, a cross talk between ERK1/2 and cAMP in pancreatic β-cell survival has been previously described (29). However, here only 43RFa elevated cAMP levels, suggesting that 26RFa-induced activation of ERK1/2 is independent of the cAMP pathway.
To further understand the effects of 43RF and 26RFa in β-cells we next determined their role on insulin secretion. To our knowledge, 43RFa effect on insulin secretion has never been studied. Of note, PTX alone had no effect here on GSIS, whereas with 26RFa, insulin levels were found increased. This is likely because glucose alone, in the absence of GPCR ligands, causes inhibition of ATP-regulated K + channels, opening of voltage-dependent Ca 2+ channels and increase in ]i), and may thus contribute to increase insulin release.
Our results indicate that the opposite effects of 43RFa and 26RFa on insulin secretion are due to activation of distinct pathways. In fact, 43RFa promotes insulin secretion, at least in part, through An open question during the study was why two peptides, that likely bind the same receptor, exert opposite effects on insulin secretion. To solve this issue, we knocked down GPR103 expression in INS-1E β-cells using specific siRNA, and found complete inhibition of 43RFa insulinotropic action, but no effect on 26RFa-induced insulin inhibition. This finding suggests that in β-cells, only 43RFa signals through GPR103, whereas 26RFa interacts with a different receptor. Accordingly, 26RFa
was found to display moderate affinity and selectivity for NPFF2, the receptor of neuropeptide FF, another member of the RFamide family (47) . Moreover, NPFF and prolactin-releasing peptide 
